EPS for Jazz Pharmaceuticals plc (JAZZ) Expected At $2.30 as of May, 8

April 16, 2018 - By Sarah North

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.09. That’s change of 0.06, from 2017Q3’s 1.03. 30 investors sold all, 89 reduced holdings as Jazz Pharmaceuticals plc ratio improved. 81 rose positions while 49 funds amassed positions. Funds hold 52.98 million shares thus 1.12% less from 2017Q3’s 53.58 million shares.
Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.2% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Fulton Savings Bank Na, Pennsylvania-based fund reported 2,902 shs. Tiaa Cref Invest Management Ltd Liability Corporation holds 0.09% or 982,030 shs in its capital. Waddell And Reed Financial accumulated 1.07M shs. Peoples Fin Corp reported 36 shs. Assetmark holds 3 shs or 0% of its capital. Alpine Woods Capital Ltd Liability accumulated 23,500 shs. Moreover, Profund Advisors Limited Liability has 0.01% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Pacad Inv reported 2,201 shs. Fifth Third Savings Bank holds 240 shs or 0% of its capital. Wells Fargo Mn reported 483,366 shs stake. Global X Co Limited Com has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 208 shs. Dearborn Prns Limited Com invested 0.02% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Bluemountain Capital Mngmt Ltd Liability Co owns 68,017 shs. Gru One Trading L P owns 35,444 shs for 0.03% of their capital.

Jazz Pharmaceuticals plc had 16 selling transactions and 0 insider purchases since December 11, 2017. This’s net activity of $3.80 million. COZADD BRUCE C sold $150,000 worth of stock or 1,000 shs. On Monday, February 26 the insider Young Matthew P. sold $460,381. On Thursday, March 1 a trade for 877 shs valued at $122,446 was made by Treacy Paul. On Tuesday, April 10 $604,345 worth of stock was sold by WILSON KAREN J. On Monday, December 11 $1.26M worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by ENRIGHT PATRICK G.

On May, 8 WallStreet awaited Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s earnings release, according to Faxor. The EPS diference is $0.89 or 63.12 % up from last years number. Previous year: $1.41; Analysts forcast: $2.30. In case of $2.30 EPS JAZZ’s profit could reach $137.55M. Analysts at Wall Street see Jazz Pharmaceuticals plc’s -10.85 % negative EPS growth compared to $2.58 EPS for last quarter. JAZZ reached $155.96 on during the last trading session after $0.11 change.Jazz Pharmaceuticals plc has volume of 403,846 shares. Since April 17, 2017 JAZZ has declined 0.32% and is downtrending. The stock underperformed the S&P500 by 11.87%.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

In total 17 analysts cover Jazz Pharmaceuticals (NASDAQ:JAZZ). “Buy” rating has 15, “Sell” are 0, while 2 are “Hold”. 88% are bullish. 29 are the (NASDAQ:JAZZ)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. In Sunday, December 3 report Cantor Fitzgerald maintained it with “Buy” rating and $200.0 target. On Tuesday, December 5 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by FBR Capital. On Wednesday, February 28 the firm has “Outperform” rating given by BMO Capital Markets. On Wednesday, February 28 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Cantor Fitzgerald. On Wednesday, November 8 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by RBC Capital Markets. On Monday, October 23 Cowen & Co maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating. Cowen & Co has “Buy” rating and $190.0 target. On Thursday, April 12 Piper Jaffray maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with “Buy” rating. On Friday, March 9 the rating was maintained by FBR Capital with “Buy”. On Thursday, January 11 the stock has “Buy” rating by BMO Capital Markets. On Tuesday, January 30 the rating was maintained by Piper Jaffray with “Buy”.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The firm is valued at $9.33 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.The P/E ratio is 19.59. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.